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Th  e story of glucose control has been one of the most 
passionate discussions in critical care medicine for nearly 
an entire decade, since publication of the landmark 
single-center trial of intensive insulin therapy targeting 
euglycemia in a cohort of mechanically ventilated surgical 
intensive care unit (ICU) patients [1]. A subsequent trial 
from the same institution involving medical ICU patients 
did not yield such strikingly positive results [2], and 
additional randomized trials have suggested no beneﬁ  t 
from this intervention [3-7] or even a modest signal of 
harm [8]. Nonrandomized trials [9-11] and a large body 
of observational cohort data from heterogeneous 
populations [12-14] suggest strongly that a J-shaped or 
U-shaped mortality curve exists among acutely and 
critically ill patients, with the lowest mortality occurring 
among those patients with mean glucose levels during 
their ICU stay in the range 90 to 120 mg/dl and higher 
rates of mortality for those patients with levels below or 
above this range.
How does one reconcile these seemingly divergent 
ﬁ  nd  ings? Clearly, based on the rules of evidence-based 
medicine, recommendations and guidelines [15,16] can-
not presently support a widespread implementation of 
insulin protocols targeting euglycemia; a more conser  va-
tive and safe eﬀ  ective glucose control approach has been 
suggested [17] and probably reﬂ  ects the current practice 
in many ICUs.
Glycemic control is considerably more complex than 
most interventions in critical care medicine, helping to 
explain variances in outcomes of the clinical trials. Very 
recently, Schultz and collaborators thoroughly reviewed 
the possible causes of discrepancies between the pioneer-
ing trial and the subsequent studies [18]. Monitoring 
issues include the use of diﬀ   erent sources of blood 
(arterial, venous, capillary) measured using a variety of 
diﬀ   erent monitoring technologies (central laboratory 
analyzer, portable arterial blood gas analyzer, bedside 
glucometer) with widely divergent degrees of accuracy 
[19-21]. Moreover, these measurements are frequently 
performed in unstable patients with dynamic degrees of 
insulin resistance and risk of hypoglycemia [22]. Each 
cycle of measure  ment and potential modiﬁ  cation  of 
therapy is time consuming, and must be repeated every 1 
to 4 hours throughout the patient’s stay in the ICU [23].
Th  e skill, motivation and experience of the treatment 
team can inﬂ  uence the protocol performance and a trial’s 
results; these factors may help explain the more positive 
results emanating from single-center trials. Th  ere were 
758 and 600 patients in the treatment arm of the two 
Leuven trials [1,2], and 800 patients in the interventional 
arm of the before-and-after Stamford trial [9], notable for 
its positive results and an absence of an increase in severe 
hypoglycemia (SH), conﬁ   rmed in several large cohort 
studies as being independently associated with increased 
risk of mortality [24-27]. In contrast, there were means of 
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tional arms of the GLUCONTROL trial [3] and the 
VISEP trial [4]. Skill with protocol performance and the 
chosen monitoring technology (portable laboratory 
analyzer vs. bedside glucometer) probably impacted not 
only the rates of SH, but also the degree to which the 
interventional cohorts achieved their targeted glycemic 
range.
Chase and colleagues reported recently in Critical Care 
that glycemic control using a highly performing 
algorithm for glycemic control resolved organ failure 
faster, and for a greater percentage of patients with 
similar admission and maximum Sequential Organ Failure 
Assessment scores, than the retrospective conven  tional 
control [28]. More  over, errors in insulin administration 
are the commonest therapeutic mistakes in ICUs [29]. 
Th   e change in the standard of care over time that resulted 
in the control arm of the most recent multicenter trial [8] 
having a glycemic target range much lower than that used 
in the ﬁ  rst Leuven trial [1] produced a lower degree of 
glycemic separation between the interventional and 
conven  tional cohorts, magnifying the importance of the 
deleterious eﬀ   ect of hypoglycemia. Th  e commonplace 
use of insulin for treatment of moderate hyperglycemia 
has therefore signiﬁ  cantly increased the size of a trial that 
would be adequately powered to potentially demonstrate 
beneﬁ  t of the intervention.
An understanding of these factors and a review of 
emerging themes relating to the dysglycemia of critical 
illness lays the groundwork for the design and creation of 
the sorts of interventional trials that will best deﬁ  ne the 
role of glycemic interventional trials in the critically ill 
patient. While previous trials have focused on control of 
overall blood glucose (BG) levels, using speciﬁ  c BG targets 
for the control and interventional arms, recent literature 
has introduced and reinforced the principle that future 
trials cannot ignore two other domains of glycemic 
control: hypoglycemia and glycemic variability (GV).
Although the authors of the Leuven 1 study reported 
that SH – deﬁ  ned as BG <40 mg/dl – that occurred in 
5.1% of the patients in the interventional arm [1] did not 
adversely aﬀ  ect outcomes, subsequent analysis of these 
data, as well as the results of several large observational 
cohort studies, suggested otherwise [30]. A retrospective 
analysis of a cohort of 5,365 patients admitted to a single 
medical–surgical ICU demonstrated that the odds ratio 
(OR) for mortality associated with a single episode of SH 
was 2.28 (95% conﬁ  dence interval (CI) = 1.41 to 3.70, 
P = 0.008) [25]. Moreover, a 1:3 nested case:control analysis 
of 102 patients with SH from this investigation matched 
to patients without SH by age, diagnostic category, 
diabetic status, treatment era and severity of illness 
conﬁ  rmed signiﬁ  cantly higher mortality in the patients 
who experienced SH (55.9% vs. 39.5%, P = 0.0057).
Similarly, Bagshaw and colleagues evaluated the highest 
and lowest glucose values among 66,184 Australian 
patients from a mix of 24 ICUs and found that a single 
episode of SH was independently associated on multi-
variable analysis with increased risk of mortality (OR = 
2.6; 95% CI = 2.1 to 3.2) [26]. Egi and coworkers recently 
published a more in-depth analysis of 4,946 patients from 
two of these 24 ICUs, and found that even mild degrees 
of hypoglycemia independently conﬁ  rmed increased risk 
of mortality as well as infection. Speciﬁ  cally, the ORs for 
mortality among groups of patients with varying levels of 
minimum BG, compared with those patients with nadir 
BG of 72 to 81 mg/dl, were as follows: 54 to 63 mg/dl, 
OR  = 1.93 (95% CI = 1.27 to 2.95, P  = 0.002); 45 to 
54 mg/dl, OR = 2.13 (95% CI = 1.29 to 3.53, P = 0.003); 36 
to 45 mg/dl, OR = 2.14 (95% CI = 1.20 to 3.81, P = 0.01); 
and <36  mg/dl, OR = 2.99 (95% CI = 1.67 to 5.37, 
P  <0.001) [27]. Pooled results from the two Leuven 
studies similarly provide support for the concept that SH 
is deleterious in critically ill patients [30]. Th  e OR for 
mortality among 2,758 medical and surgical ICU patients 
was 3.23 (95% CI = 2.25 to 4.64, P <0.0001).
Finally, hypoglycemia is correlated with severity of 
illness in some studies [25] but not all [30]. While multi-
variable logistic regression modeling cannot completely 
exclude the problem of residual confounding, this type of 
analysis will be the strongest level of evidence available to 
clinicians; there will never be a randomized, controlled 
trial of induced hypoglycemia or deliberately increased 
GV in a cohort of critically ill patients.
Th  ere are two clear implications from these studies. 
First, there can be no doubt that the outcomes of the 
major interventional trials on intensive insulin therapy in 
various critically ill populations were signiﬁ  cantly 
aﬀ  ected by the high rates of SH that occurred among 
patients in their interventional arms, ranging from 6.8% 
of the patients in the NICE-SUGAR trial [8] to 18.7% in 
the Leuven medical ICU trial (25.0% of those in the ICU 
for 5 days or more) [2]. Second, future glycemic manage-
ment interventions must be designed to minimize the 
occurrence not only of SH, but also of mild to moderate 
hypoglycemia.
While GV was not on any investigator’s radar screen 
during design, implementation or publication of the 
interventional trials of glycemic control in the critically 
ill, new literature has identiﬁ   ed GV as an aspect of 
glycemic control that may have an even larger bearing on 
outcomes than does reduction of overall glycemic levels. 
A retrospective analysis of a cohort of 3,252 patients 
admitted to a mixed medical–surgical ICU found that 
those patients in the lowest quartile of GV – based on the 
standard deviation of the mean glucose level – had an OR 
for mortality of 0.49 (95% CI = 0.38 to 0.63, P <0.0001), 
while those in the highest quartile of GV sustained an 
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2.22) [31]. Indeed, among patients with a mean glucose 
level of 70 to 99 mg/dl during their ICU stay – at ﬁ  rst 
glance, the patients with the best glycemic control – the 
mortality ranged from 5.9 to 30.1% compared with those 
patients with the lowest and highest variability.
Additional work from this institution demonstrated 
that the deleterious eﬀ  ect of increased GV was seen only 
among nondiabetic patients [32], in concordance with a 
stream of literature suggesting that hyperglycemia in 
critically ill patients has a much greater adverse eﬀ  ect 
among nondiabetics than among diabetics [33-35]. Other 
retrospective investigations among a variety of diﬀ  erent 
patient populations have conﬁ  rmed that increased GV is 
independently associated with increased risk of mortality 
[36-39].
Finally, the Leuven investigators recently published the 
ﬁ   rst analysis of the eﬀ   ect of GV in a prospective 
randomized controlled trial [30]. Th   is important investi-
ga tion  conﬁ  rmed that increased GV was independently 
associated with increased risk of mortality, both in the 
medical ICU and the surgical ICU studies. Moreover, the 
intervention – intensive insulin therapy – failed to reduce 
GV, and in fact tended to increase GV in both cohorts. 
Failure to improve GV may therefore have diminished 
the beneﬁ  cial eﬀ  ects of the intervention, providing support 
for the inclusion of this domain of glycemic control as a 
secondary endpoint in future interventional trials [40].
Th  e importance of these observations is strengthened 
by their biologic plausibility. Indeed, in vitro, a high 
glucose variability can induce apoptosis of endothelial 
cells and impairment of the cellular signaling in mono-
cytes [41,42]. Th  ese eﬀ  ects may be mediated via wide 
changes in osmolarity that in turn could aﬀ  ect cellular 
and organ function [43]. Previous investigations in 
diabetics have suggested that serum markers of endo-
thelial dysfunction and oxidative stress are increased in 
those patients who experience glucose ﬂ  uctuation 
independent of the average glucose exposure [44]. Harm 
to the micro  vas  culature mirrored by the elevation of 
markers of endothelial dysfunction could hence be further 
acceler  ated by hyperactive inﬂ   ammatory cells. Finally, 
although the most speculative, perhaps the most 
important reason why increased GV may be associated 
with worsened ICU outcomes is the fact that signiﬁ  cant 
hypoglycemia could occur undetected. Because 
continuous glucose monitor  ing has not yet been widely 
used in ICU patients, no active surveillance program can 
eliminate the possibility that signiﬁ  cant glucose swings 
are occurring.
Future interventional trials of insulin therapy in 
critically ill patients must therefore control all three 
domains of BG control: lowering overall glycemic levels, 
while minimizing both GV and hypoglycemia. Th  ere  are 
several approaches that may, in combination, help ICU 
teams achieve the best possible outcomes [45]. One such 
approach is the use of computerized algorithms to improve 
work ﬂ   ow, increase adherence to glycemic targets and 
minimize errors in insulin dosing, resulting in decreased 
rates of hypoglycemia. In fact, a large multicenter French 
trial – Computerized Glucose Control in Critically Ill 
Patients (CGAO-Rea, Clinicaltrials.Gov NCT01002482) – 
is currently underway to compare the outcome of 
patients randomized to computer-guided glucose control 
versus usual care [46]. Additionally, substantial improve-
ments in glycemic protocol performance and decreases 
in the time burden of the intervention are likely to accrue 
from the use of accurate continuous or near-continuous 
glucose monitoring technologies [47,48].
Th   e increased frequency of monitoring resulting from 
the use of these new monitors should eliminate the 
occurrence of SH, and should markedly reduce the 
occurrence of mild to moderate hypoglycemia since the 
nursing staﬀ    attending the patient will have adequate 
warning to correct the trajectory of BG values before 
they reach dangerous levels. Moreover, continuous or 
near-continuous monitoring technology will provide 
clinicians with a tool to minimize GV, especially with the 
integration of insulin and nutrition delivery into the 
treatment algorithms.
In conclusion, glucose can no longer be considered an 
innocent bystander in the ICU; both hyperglycemia and 
hypoglycemia harm our patients. Th  e lessons we have 
learned from the interventional trials performed over the 
past 9 years and the compelling evidence from recent 
investigations regarding the impact of hypoglycemia and 
GV lay the groundwork for the design and imple  men-
tation of the next generation of trials. While many 
unanswered questions remain, there can be consensus 
that the literature has moved past the paradigm of a pro–
con debate and towards a deeper appreciation of the 
importance of glycemic control in the critically ill patient 
and the challenges that clinicians still face.
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